Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target at $8.20

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have received a consensus rating of “Hold” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.60.

Several research firms have issued reports on RXRX. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC dropped their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Morgan Stanley reduced their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Accel Wealth Management purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $310,000. Avanza Fonder AB bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $580,000. Institute for Wealth Management LLC. bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at $3,928,000. Norges Bank purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at $23,429,000. Finally, Invesco Ltd. increased its position in shares of Recursion Pharmaceuticals by 54.6% during the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company’s stock valued at $1,207,000 after buying an additional 63,068 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Up 0.8 %

Shares of RXRX opened at $4.20 on Monday. The firm has a market capitalization of $1.69 billion, a P/E ratio of -2.74 and a beta of 0.99. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a 50-day simple moving average of $5.62 and a 200-day simple moving average of $6.69.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.39) earnings per share. On average, equities research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.